Patent · US Active

Pharmaceutical antibody compositions with resistance to soluble CEA

US8901278B2 · kind B2 · utility

3Cited by

2References

2Claims

0Family size

Assignee

AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

Doris Rau · Munich, DE
Susanne Mangold · Munich, DE
Peter Kufer · Munich, DE
Tobias Raum · Munich, DE

Key dates

Filing date	Dec 13, 2011
Grant date	Dec 2, 2014
Priority date	—
Expiry date	May 5, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/732
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” (SEQ ID NO: 29) and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” (SEQ ID NO: 28) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27) or (ii) a CDR-H1 having the amino acid sequence “TYAMH” (SEQ ID NO: 31) and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” (SEQ ID NO: 30) and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” (SEQ ID NO: 27). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.